Otezla (apremilast) Letter of Medical Necessity
Otezla (apremilast) is often a non-injectable alternative for patients who cannot tolerate or prefer to avoid biologics. LMNs should highlight patient-specific reasons biologics are inappropriate.
FDA-Approved Indications
- ● plaque psoriasis
- ● psoriatic arthritis
- ● oral ulcers of Behçet's disease
Why Otezla Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Topical therapy trial inadequate
- 2. csDMARD not tried for PsA
- 3. Cost vs alternative oral therapies
- 4. Quantity limit
What to Include in a Otezla Letter of Medical Necessity
Document diagnosis, prior topical or systemic therapy trials, contraindications to biologic therapy (e.g., needle aversion, infection risk, prior malignancy), and the clinical rationale for an oral PDE4 inhibitor.
Key clinical evidence to cite:
- ✓ ESTEEM 1 & 2, PALACE 1-4 trials
- ✓ Favorable safety profile vs biologic alternatives
Relevant guidelines:
- 📖 AAD-NPF 2019 Psoriasis Guidelines
- 📖 GRAPPA 2021 PsA Recommendations
Otezla Prior Authorization Criteria
Standard criteria across major US payers for Otezla. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Topical therapy trial inadequate
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Otezla
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Otezla Prior Authorization FAQ
Why was my Otezla prior authorization denied?
The most common denial reasons for Otezla are: Topical therapy trial inadequate; csDMARD not tried for PsA; Cost vs alternative oral therapies; Quantity limit.
What should a Otezla Letter of Medical Necessity include?
Document diagnosis, prior topical or systemic therapy trials, contraindications to biologic therapy (e.g., needle aversion, infection risk, prior malignancy), and the clinical rationale for an oral PDE4 inhibitor.
Which payers cover Otezla?
Otezla is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Express Scripts, CVS Caremark, though formulary tier and prior authorization criteria vary.